{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "HURN",
  "name": "Huron Consulting Group Inc.",
  "url": "https://frontierpicks.com/dossiers/HURN/",
  "json_url": "https://frontierpicks.com/dossiers/HURN.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a3",
    "n": 3
  },
  "current_thesis": "AI-disruption discount still unwinding, but the last leg bought nothing new: price ran from the 2026-08-07 close of $152.05 to $161.64 on 2026-08-21 with no guidance change since the 2026-07-28 beat-and-raise — just a fifth covering analyst and two 07-29 target hikes. No company event resolves anything before the unscheduled Q3 print.",
  "invalidation_trigger": "A weekly close below $132 unwinds the re-rating that followed the 2026-07-28 guidance raise; secondarily, FY2026 RBR guidance marked below the $1.85B floor, or organic RBR decelerating to mid single digits from 10.8%, at the Q3 print.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "ai-datacenter-infrastructure",
    "managed-care-health-services",
    "small-cap-value-rotation"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Huron guides and is scored on revenues before reimbursable expenses (RBR); total revenue is a larger, different number (Q2 2026 total revenue was reported around $475M vs RBR $465.6M).",
    "Coverage is five sell-side analysts as of 2026-08-21, up from four two weeks earlier — consensus target and estimates can move materially on a single note.",
    "No dividend. Capital return is entirely buyback, run against $812.8M long-term debt and $31.2M cash at 2026-06-30.",
    "Fiscal year equals calendar year. The Q3 2026 release date was not announced as of 2026-08-22; prior-year Q3 reports landed in late October, with the date confirmed roughly three weeks ahead."
  ],
  "body_markdown": "\n_Refresh of coverage first published 2026-07-30, last updated 2026-08-08. Price reference: the 2026-08-21 close of $161.64._\n\n## HURN — Huron Consulting Group Inc.\n\n## Current Thesis\n\nThe leg on offer is unchanged: a services compounder that spent H1 2026 being priced as an AI casualty, then printed record demand. What has changed since the 2026-08-08 note is that price has kept going without a single new operating datapoint. Shares moved from the 2026-08-07 close of $152.05 to $161.64 on 2026-08-21 with no guidance update, no investor day and no company event in between — the entire August extension is multiple expansion on the 2026-07-28 numbers (RBR $465.636M vs $448.969M consensus, adjusted EPS $2.46 vs $2.17, organic RBR +10.8%, FY26 EPS guide lifted to $9.00–9.40 from $8.35–9.15).\n\nThe audience has widened rather than the fundamentals. Stockanalysis.com showed four covering analysts and a $190.25 mean target on 2026-08-07; on 2026-08-21 it showed five analysts and $190.75, with the range at $160–$215 against $165–$240 two weeks earlier. Two target raises are dated 2026-07-29: Truist's Tobey Sommer to $175 from $155, Barrington's Kevin Steinke to $213 from $207. The $185.58 52-week high is still unreclaimed, with the 2026-08-21 close 12.9% beneath it.\n\n## Bull Case\n\n- **The raise cleared the Street, not just the quarter (2026-07-28).** FY2026 RBR guidance went to $1.850–1.890B from $1.780–1.860B against $1.827B consensus; adjusted EPS to $9.00–9.40 from $8.35–9.15 against $8.84. The new EPS floor sits above where consensus had been.\n- **Healthcare is both the biggest and fastest leg.** Q2 2026 Healthcare RBR $232.3M, +17.4% YoY, roughly half of segment RBR, with approximately 12% organic. Healthcare managed services grew 64% YoY, 43% of it organic — the recurring, outsourced end of the book compounding fastest.\n- **Digital reversed the line the bear case pointed at.** Digital capability RBR $189.7M, +9.4% YoY in Q2 2026, after the Healthcare digital line contracted 7% in Q1 2026.\n- **Commercial inflected off a small base.** Q2 2026 Commercial RBR $94.0M, +24.6% YoY.\n- **Sell-side moved with the print and has stayed there.** Both 2026-07-29 target raises came after the release; the 2026-08-21 mean of $190.75 sits above the $161.64 close, and the low end of the range ($160) is roughly at spot.\n- the quarter in which the stock traded near its $100.10 low.\n\n## Bear Case\n\n- **The August advance bought nothing new.** Between the 2026-07-28 release and the 2026-08-21 close, no guidance change, no operating update and no scheduled company event occurred. Price is discounting the same $9.00–9.40 EPS frame at a higher multiple.\n- **The top of the target range compressed while the mean drifted up.** stockanalysis.com's range moved from $165–$240 (2026-08-07) to $160–$215 (2026-08-21). The mean rose $0.50; the high fell $25 and the low fell $5.\n- **Directors sold into strength, in small size.** Hugh E. Neither is large enough to read as distribution, and one is plan-driven — but both are sales, and both are dated inside the run.\n- **Capital return is levered.** At 2026-06-30: $31.2M cash against $812.8M long-term debt and $20.0M of current maturities.\n- **Headline growth is acquisition-assisted.** Healthcare's +17.4% headline against roughly 12% organic; group organic RBR +10.8% is the number that carries the guide once acquisition contribution anniversaries.\n- **Education is the slow leg with policy exposure.** Q2 2026 Education RBR $139.4M, +7.8% YoY. NIH FY2026 program-level funding of $47.5B is a 1% increase over FY2025 under the Consolidated Appropriations Act, 2026, after a proposed 40% cut was rejected.\n- **Margin still has to build.** Q2 2026 adjusted EBITDA margin was 15.6% of RBR against 13.6% year-to-date, versus a full-year frame of 14.5%–15.0%.\n\n## Setup & Price Structure\n\n- Close $161.64 on 2026-08-21; 12.9% below the $185.58 52-week high; a three-month price change of +53.3%.\n- RSI(14) read 65.2 on 2026-08-21 against 70.8 on 2026-08-07, while price rose over the same ten sessions. That is a momentum reading easing as price advances — a ten-session window is too short to call a divergence, so it is logged as an observation rather than a signal.\n- Simply Wall St, 2026-08-19: shares around $158.98, market capitalisation roughly $2.57B, up about 33% over the prior month.\n- **The narrative is maturing.** The surprise is dated 2026-07-28 and is now three-plus weeks old; participation is still widening (a fifth covering analyst appeared on the stockanalysis.com page between 2026-08-07 and 2026-08-21) and retail-facing syndicated pieces clustered mid-August — Yahoo Finance carried \"Is AI Fears Overblown for This Consulting Stock?\" and a Simply Wall St item framing the shares as roughly 18% undervalued \"following its recent run.\" That is second-wave coverage arriving after the move, which is what separates maturing from accelerating. It is not saturated: five analysts, a ~$2.57B capitalisation and an unreclaimed 52-week high are not mainstream saturation.\n- **Crowding observables, stated flat:** coverage count 4 → 5 in two weeks; two target hikes both dated 2026-07-29; two director sales dated 2026-08-11 and 2026-08-14; retail-sentiment articles clustering 2026-08-19; no earnings date inside 30 days; price extended above the level of the prior note with the momentum reading lower.\n- The 2026-08-14 13F deadline has passed. No aggregated Q2 2026 ownership change for Huron surfaced in this review, so institutional behaviour through the H1 drawdown to $100.10 remains unmeasured here — a gap, not a finding.\n- The structural level that defines the thesis, unchanged from the prior note, sits at the post-print gap area rather than at the August extension: a weekly close below $132 puts price back where it traded before the guidance raise.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-09-17 (est., unconfirmed):** September small-cap virtual investor conference season. Huron presented at Sidoti's September conference on 2025-09-18, announced 2025-09-05. No 2026 appearance has been announced. If it happens it is the only forum for management commentary between the July raise and the Q3 print.\n- **~2026-10-27 (est.) — possibly November:** Q3 2026 results. The date is not announced as of 2026-08-22. Huron's Q3 releases have historically landed in late October, but a transcript summary of the 2026-07-28 call references management pointing to November for the next report. Either way it falls outside 30 days, and it is the event that settles whether the $1.850–1.890B RBR and $9.00–9.40 EPS guide holds.\n\n## Elapsed catalysts\n\n- **Nothing company-scheduled is confirmed inside the window as of 2026-08-22.** *(passed 4d ago)*\n\n## What Would Change Our Mind\n\nThe fundamental break is a guide-down: FY2026 RBR marked below the $1.85B floor set on 2026-07-28, or adjusted EPS guidance falling back under $9.00. That single line is what the July re-rating was purchased on, and it reverses the read directly rather than gradually.\n\nAlso mind-changing, in order of how quickly it would show:\n\n- Organic RBR decelerating to mid single digits from 10.8%, with the Healthcare headline-versus-organic gap (+17.4% vs ~12%) widening as acquisition contribution anniversaries.\n- Digital capability RBR turning negative year-over-year again after +9.4% in Q2 2026 — the specific line the AI-substitution argument targets.\n- Q3 adjusted EBITDA margin printing below the 14.5%–15.0% full-year frame while year-to-date sits near 13.6%, leaving the EPS raise unfunded.\n- Quarterly repurchases dropping well below the $53.1M / 438,456-share Q2 pace, or new debt raised against $31.2M of cash to fund them.\n- On price: a weekly close below $132 unwinds the post-raise advance and returns the shares to their pre-print range. A move above $185.58 on volume would mark the discount as fully closed and shift the question from re-rating to growth multiple.\n- On the calendar: the mid-September conference window passing with no appearance would extend the news vacuum to roughly ten more weeks, leaving price to run on flow alone.\n\n## Correlation Notes\n\n- The de-rating that created this setup was sector-applied, not company-specific: the argument that AI compresses billable consulting hours hit listed professional-services names as a group. That makes the read partly a function of how peer consulting and staffing companies guide, not only how Huron prints. This is an inference about the mechanism, not a measured beta.\n- Roughly half of segment RBR is Healthcare, tying results to hospital margin pressure and reimbursement cycles; the Education leg ties to federal research appropriations, where the FY2026 NIH figure is $47.5B (+1% over FY2025).\n- With five covering analysts and a capitalisation near $2.57B (2026-08-19), a single note can move the consensus target materially — the mean shifted while the range compressed by $25 at the top inside two weeks.\n- Despite the AI framing, there is no data-centre or semiconductor capex exposure here. The AI linkage runs through demand substitution for services, so the name should not be expected to track AI-infrastructure hardware complexes.\n- Small-capitalisation beta applies: a $53.3% three-month advance in a Russell-scale name typically gives back more than the index in a broad risk-off tape.",
  "first_seen": "2026-07-30",
  "last_analyzed": "2026-08-22T09:07:50+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}